Biotech Most Active Stocks: Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals (NASDAQ:ARIA), Arena Pharmaceuticals (NASDAQ:ARNA), MannKind Corporation (NASDAQ:MNKD)

Gilead Sciences, Inc. (NASDAQ:GILD) was active yesterday as one Bloomberg reporter thinks he has another take on the recent Waxman letter. Drew Armstrong — via his own Twitter account — said Gilead execs had a meeting scheduled with Waxman all along and the letter just seemed like Waxman was making an effort to drag them in. Gilead Sciences, Inc. (NASDAQ:GILD) stock performance was 3.37% in … Continue reading Biotech Most Active Stocks: Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals (NASDAQ:ARIA), Arena Pharmaceuticals (NASDAQ:ARNA), MannKind Corporation (NASDAQ:MNKD)

Healthcare Active Runners: Merck & Co. (NYSE:MRK), Johnson & Johnson (NYSE:JNJ), Pfizer Inc. (NYSE:PFE), Ariad Pharmaceuticals (NASDAQ:ARIA)

Merck & Co., Inc. (NYSE:MRK) is getting close to conducting phase 3 trials for a combination treatment for Hepatitis C, which could potentially rejuvenate the pharmaceutical giant’s revenue growth. The clinical data for a combination of drugs MK-5172 and MK-8742 has showed high cure rates among patients with genotype 1 of the disease, and this has encouraged Merck to move to phase 3 trials. Merck … Continue reading Healthcare Active Runners: Merck & Co. (NYSE:MRK), Johnson & Johnson (NYSE:JNJ), Pfizer Inc. (NYSE:PFE), Ariad Pharmaceuticals (NASDAQ:ARIA)

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) is 6.6% higher, as traders digest rumors that Jazz Pharmaceuticals plc (NASDAQ:JAZZ) was willing to pay over $20 per share to buy the firm. Digging deeper, speculators are expecting ARIA to remain south of $9 in the short term, buying to open the April 9 and May 9 puts. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock performance was 5.00% in last session and … Continue reading Biotech Bullish Stocks: Ariad Pharmaceuticals (NASDAQ:ARIA), Idera Pharmaceuticals (NASDAQ:IDRA), CytRx Corporation (NASDAQ:CYTR), Corcept Therapeutics Incorporated (NASDAQ:CORT)

Earlier this week, Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that it has initiated a phase II pivotal study that will evaluate the safety and efficacy of AP26113 in locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients who had previously been treated with Pfizer’s (PFE – Analyst Report) Xalkori (crizotinib). Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock performance was -1.16% in last session and finished the … Continue reading Biotech Active Movers: Ariad Pharmaceuticals (NASDAQ:ARIA), Insmed Incorporated (NASDAQ:INSM), Rexahn Pharmaceuticals (NYSEMKT:RNN), Inovio Pharmaceuticals (NYSEMKT:INO)

Hemispherx Biopharma, Inc. (NYSE MKT:HEB) participated in the 11th Biennial International Research and Clinical Conference held in San Francisco, California, USA, March 20-23, 2014. The title of the presentation is “Differential Exercise Responses to Rintatolimod [Ampligen(R)] Exhibited by Patients with Severe Chronic Fatigue Syndrome (CFS)”. This Phase III prospective, double-blind, randomized, placebo-controlled trial was conducted at twelve centers by leading researchers in fatigue and post-exertional … Continue reading Biotech Active Runners: Hemispherx BioPharma (NYSEMKT:HEB), Rexahn Pharmaceuticals (NYSEMKT:RNN), Arena Pharmaceuticals (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA)

JA Solar Holdings Co (NASDAQ: JASO) is projected to report its Q4 earnings at $0.01 per share on revenue of $291.82 million. JA Solar Holdings Co., Ltd. (ADR) (NASDAQ:JASO) stock performance was 8.25% in last session and finished the day at $11.42. Traded volume was 1,600.00million shares in the last session and the average volume of the stock remained 2.48million shares. The beta of the … Continue reading Top Gainers: JA Solar Holdings (NASDAQ:JASO), magicJack VocalTec (NASDAQ:CALL), Ariad Pharmaceuticals (NASDAQ:ARIA), Millennial Media (NYSE:MM)